How the cell coordinates the diverse actions of Rap1 into a coherent physiological response probably depends on the cell type and the mode of activation of the small GTPase. Many signals converge at Rap1 via different types of Rap1 guanine nucleotide exchange factors (Rap1-GEFs), including C3G regulated by receptor tyrosine kinases, Epac regulated by c-AMP and CalDAG-GEF activated by calcium and diacylglycerol whereas Rap1 inactivation involves cell type specific GTPase-activating proteins (Rap1-GAPs). A principal Rap1-GAP in hematopoietic cells is signal-induced proliferation associated gene (SPA-1) and mice knock-out for Spa-1 gene develop a spectrum of myeloid disorders that resemble human chronic myelogenous leukemia and MDS. In these Spa-1-deficient mice, ERK is constitutively activated in the absence of Ras activation. 6 The cooperative functions of Ras/ERK and Rap1 and the role of Rap1 activation in the context of myeloid cells suggest that deregulated Rap1 could deliver an oncogenic signal to these cells in vivo. This hypothesis led us to test whether RAP1 genes could be mutated in bone marrow mononuclear cells from MDS patients.
Bone marrow samples were obtained by sternal aspiration from 85 MDS patients and four normal donors, and mononuclear cells were isolated before RNA and/or DNA extraction. First, we looked for RAP1A and RAP1B mutations on RNA samples in 29 patients whose main characteristics are described in Table 1 and two control samples. This screening was performed by reverse transcription-polymerase chain reaction (RT-PCR) and direct sequencing of cDNAs using the primer pairs previously published elsewhere. 7 Among the 31 samples, no mutation was identified in RAP1A cDNA and one mutation was found in the RAP1B transcript isolated from a RAEB sample Table 1 Main characteristics of the two series of studied patients (n ¼ number of cases) (RAEB with del(7q)). This mutation was a G12R and K42R double-point mutation ( Figure 1a ) that involved highly conserved amino acids (Figure 1b ). This result was obtained twice starting from reverse transcription. The G12R mutation is equivalent to those which produce oncogenic Ras and is more likely an activating mutation than a polymorphism. 8 The sequence profile did not demonstrate any residual normal sequence. The corresponding karyotype did not show any alteration of chromosome 12 on which RAP1B gene is located. Such a profile could indicate that (i) the abnormal allele has been preferentially amplified, (ii) a homozygous mutation or heterozygous mutation with loss of heterozygosity of the normal allele has occurred. Unfortunately, genomic DNA of this patient was not available for further investigation. As the sensitivity of PCR followed by direct sequencing remains low, we looked for mutations of the RAP1B gene in genomic DNA samples obtained from bone-marrow mononuclear cells of 56 additional patients whose characteristics are summarized in Table 1 and two normal donors. Since the double-point mutation identified by PCR in one patient involved amino acids 12 and 42, we explored the first two coding exons of the gene (exons 2 and 3) that encode these amino acids. To look for unknown mutations, we chose genomic DNA amplification followed by heteroduplex formation and Denaturant Gradient Gel Electrophoresis (DGGE) as a sensitive and reliable method to screen for mutated products among normal alleles in MDS bone marrows. Genomic DNA was amplified by PCR with primers designed to encompass exons 2 and 3 of RAP1B, with the addition of a GC-clamp on the 5 0 end of each 3 0 primer. Primers used for RAP1B exon 2 amplification were: 5 0 -TACACAACTTTACTTA GAATTCTT-3 0 and 5 0 -GCCCGCCGTCCCGGCCCGACCCCC GCGCGTCCGGCGCCCGCTTGGAGTGAAAGGCTTAGGT-3 0 . Primers used for RAP1B exon 3 were 5 0 -GTATAATGGTTTCT TAATTTTTTT-3 0 and 5 0 -GCCCGCCGTCCCGGCCCGACCCCC GCGCGTCCGGCGCCCGCTCAAAAGCAAAACCTTCC-3 0 . Heteroduplexes were resolved on polyacrylamide gel containing a Figure 1 RAP1B mutation found in one patient. (a) RNA was reverse transcribed to cDNA, the RAP1B cDNA was amplified by PCR and sequenced. Sample #1 represents a normal control and sample #2 is a RAEB patient with two mutations at G12R and K42E indicated with arrows. (b) Alignment of the N-Ras, K-Ras, H-Ras, Rap1A and Rap1B protein sequences. The two mutations in Rap1Bn are found on highly conserved amino acids (arrows).
gradient of urea and formamide, stained with ethidium bromide and photographed under UV transillumination. To determine the sensitivity of DGGE in detecting RAP1B mutations, random mutagenesis was performed in RAP1B exons 2 and 3. Two mutated PCR products were obtained both in exon 2. Each mutated plasmid was mixed with nonmutated plasmid at different ratios. DGGE analysis detected mutated DNA when representing as low as 10% of the total studied DNA. Using this technique, we did not detect any mutation in RAP1B genomic DNA in the 56 tested samples. We conclude that RAP1A or RAP1B gene mutation is a rare event in MDS bone marrow cells.
The main activation mechanisms of p21 Ras proteins in human tumors are single amino acid substitutions at amino acid 12 (glycine), 13 (glycine) and 61 (glutamine) that significantly reduce the intrinsic GTPases activity of Ras proteins and create a transforming protein. 8 Genomic DNA was analysed in the 56 patients by heteroduplex high-pressure liquid chromatography (HPLC) under denaturating conditions, as previously described. 2 Abnormal profiles were sequenced to confirm the mutation. We found a mutation in N-RAS or K-RAS at codons 12/13 or 61 in seven of 56 studied patients (12.5%), which is in accordance with previous studies in the literature. These mutations were identified mainly in high-grade MDS, including RAEB and secondary AML.
Deregulation of Rap1 signaling has been identified in malignancies, for example, the Rap1-GEF, CalDAG-GEF, is activated by proviral insertion in a leukemia-prone strain of mice, and the Bcr-Abl fusion tyrosine kinase that plays a central role in chronic myelogenous leukemia, activates both the Ras/ Raf-1 and the Rap1/B-Raf pathways. On the other hand, mutations in RAP1 genes have rarely been investigated in human tumors. In a small series of patients with cold thyroid follicular adenomas, no mutation was identified in either Epac or Rap1. 7 Although RAP1 does not appear as a frequent target for mutagenesis, its activation could participate to malignant phenotype either by activating the B-Raf/MEK/ERK signalling pathway or by stimulating integrin activation and chemokineinduced migration, both favouring hematopoietic cell survival outside of their normal microenvironment in the bone-marrow. Other mechanisms leading to the dysregulated activation of Rap1 could contribute to the pathophysiology of myeloid disorders such as MDS. M Fontenay 
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